Preoperative CA 19.9 Level Predicts Lymph Node Metastasis in Resectable Adenocarcinoma of the Head of the Pancreas.

Preoperative CA 19.9 Level Predicts Lymph Node Metastasis in Resectable Adenocarcinoma of the Head of the Pancreas: a Further Plea for Biological Resectability Criteria.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05959213

Acronym

ICALYRA

Enrollment

2034

Registered

2023-07-25

Start date

2000-01-01

Completion date

2023-03-01

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreas Cancer

Keywords

Ca 19.9, Pancreatic adenocarcinoma, Pancreatoduodenectomy

Brief summary

In our multicenter retrospective study, preoperative CA 19.9 levels predicts the presence of lymph node metastasis at final histology in patients underwent pancreatoduodenectomy for pancreatic ductal adenocarcinoma .

Detailed description

A retrospective analysis have been conducted on more than 2.000 patients underwent pancreatoduodenectomy for pancreatic ductal adenocarcinoma radiologically resectable at the preoperative staging. Preoperatory levels of CA 19.9 were measured in order to identify a relation with nodal involvement at the pathological staging.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All patients undergone pancreatoduodenectomy * No preoperative radiological suspicion of lymph node metastases.

Exclusion criteria

\- Age \< 18

Design outcomes

Primary

Measure	Time frame	Description
Quantitative data - Preoperatory levels of CA 19.9 (U/ml)	20 years	Define relation of quantitative data (CA 19.9 (U/ml)) with nodal positivity at the final pathological report

Outcome results